DESIGN AND DEVELOPMENT OF MONTELUKAST SODIUM FAST DISSOLVING FILMS FOR BETTER THERAPEUTIC EFFICACY

PRABHAKAR VISHVAKARMA*
Pharmaceutics Research Lab, Vivek College of Technical Education, Bijnor

ABSTRACT

The oral route is most popular route for the administration of therapeutic agents because of the low cost of therapy and ease of administration lead to high levels of patient compliance. The most popular oral solid dosage forms are tablets and capsules. Many patients find it difficult to swallow tablets and hard gelatin capsules particularly pediatric and geriatric patients and do not take their medicines as prescribed. The objective of this research was to prepare fast dissolving oral thin film (FDTF) containing Montelukast sodium is indicated for the prophylaxis and chronic treatment of asthma to enhance convenience and compliance to the elderly and pediatric patients for better therapeutic efficacy. The present investigation was undertaken with the objective of formulating of the montelukast sodium fast dissolving oral thin films allowing fast reproducible drug dissolution in oral cavity thus bypassing first pass metabolism. The film were prepared by using polymers such as hydroxypropyl methyl cellulose (HPMC) and Maltodextrin, plasticizer such as PEG 400, by a solvent casting method. They were evaluated for physical characteristics such as thickness, uniformity of weight, folding endurance, drug content, surface ph, percentage elongation and tensile strength, drug polymers compatibility by FTIR study, scanning electron microscopy and in vitro drug release. The formulations were subjected to disintegration, in-vitro drug release test. The in vitro disintegration time of the optimized batch F4 was found to be 20 sec. The optimized batch was found to be stable for 1 month under specified stability conditions.

Keywords: BisoprololFumarate, Fast dissolving film, HPMC, Maltodextrin, Solvent casting method, 31 factorial. The formulations were subjected to disintegration, in-vitro drug release test. The in vitro disintegration time of the optimized batch F4 was found to be 20 sec. The optimized batch was found to be stable for 1 month under specified condition.

INTRODUCTION

Among the different routes, the most agreeable route for the patients is oral route. Most of the pharmaceutical companies have directed their search activity in developing viable dosage alternatives from oral route for pediatrics, geriatric, noncompliant or nauseous patients. Research in the oral drug delivery system has led to evolution of dosage forms from simple conventional tablets/capsules to modified release tablets/capsules to oral disintegrating tablet to sustained release capsules to modified release capsules to oral disintegrating tablets and films to modified release tablets/capsules to oral disintegrating tablet to film. Fast dissolving oral film, a novel drug delivery system for the oral delivery of the drugs is an ultra-thin film prepared using hydrophilic polymers that rapidly dissolve on the top or the floor of the tongue or buccal cavity. It is an ultrathin strip (50-150 microns thick) of postage stamp size with an active agent and other excipients developed on the basis of transdermal patch technology.1,2 Fast-dissolving drug-delivery systems were first developed in the late 1970s as an alternative to tablets, capsules, and syrups for pediatric and geriatric patients who experience difficulties swallowing traditional oral solid-dosage forms. The novel technology of oral fast-dispersing dosage forms is known as fast dissolve, rapid dissolve, rapid melt and quick disintegrating tablets. However, the function and concept of all these dosage forms are similar. By definition, a solid dosage form that dissolves or disintegrates quickly in the oral cavity, resulting in suspension or dissolution without the need for the administration of water, is known as an oral fast-dispersing dosage form. Difficulty in swallowing (dysphagia) is common among all age groups, especially in elderly, and is also seen in swallowing conventional tablets and capsules. An estimated 35% of the general population, and an additional 30.40% of elderly institutionalized patients and 18.22% of all persons in long-term care facilities, suffer from dysphagia. This disorder is associated with many medical conditions, including stroke, Parkinson’s, AIDS, thyroidectomy, head and neck radiation therapy, and other neurological disorders, including cerebral palsy.3,4 One study showed that 26% of 1576 patients experienced difficulty in swallowing tablets. The most common complaint was tablet size, followed by surface, form and taste. The problem of swallowing tablets was more evident in geriatric and pediatric patients, as well as traveling patients who may not have ready access to water.5,6 Formulation of these systems is usually straightforward; the polymer and drug are dissolved in a solvent and a film is cast by solvent evaporation.7,8 Most commercially available oral thin formulations, such as Oral film TM, (benzocaine) or Theraflu ®, (dextromethorphan/Phenylephrine HCl or Diphenhydramine HCl) are designed to deliver locally acting drugs or for mouth-freshening (such as Listerine Pocket Pak TM.). Montelukast sodium is a leukotriene receptor antagonist (LTRA) used in maintenance treatment of asthma and to relieve symptoms of seasonal allergies.9 It is usually administered orally. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in lungs and bronchial tubes by binding to it. This reduces the bronchoconstriction otherwise caused by the leukotriene, and results in less inflammation. Montelukast sodium bioavailability is 63%. It has extensive first-pass metabolism and show a very poor dissolution rates in order to overcome this problem preparation of oral thin films. The main objectives of the present study were to prepare and evaluate the oral thin films of montelukast sodium and to study the various formulation variables that affect in vitro performance.10,11

Criteria for Fast Dissolving Film14,15:
Fast dissolving film should
• Have a pleasant mouth feel.
• Not require water to swallow, but it should dissolve or disintegrate in the mouth in matter of seconds.
• Be compatible with taste masking.
• Leave minimum or no residue in the mouth after oral administration.
• Exhibit low sensitivity to environmental conditions such as temperature and humidity.

Advantages of FDTF14,17:
• Ease of administration to pediatric, geriatric, bedridden patients and psychiatric patients who refuse to swallow tablets.
• No need of water to swallow the dosage form, which is highly convenient feature for patients who are traveling.
• Rapid dissolution and absorption of drug, which may produce rapid onset of action.
• Some drugs are absorbed from the mouth, pharynx and esophagus as the saliva passes down into the stomach, which enhances bioavailability of drugs.
• Pregastric absorption can result in improved bioavailability and as a result of reduced dosage; improved clinical performance through a reduction of unwanted effects.
• Good mouth feel property helps to change the perception of medication as bitter pill particularly in pediatric patient.
• The risk of choking or suffocation during oral administration of conventional formulation due to physical obstruction is avoided, thus providing improved safety.
• Useful in cases where an rapid onset of action required such as in motion sickness, sudden episodes of allergic attack or coughing, bronchitis or asthma.
• An increased bioavailability, particularly in cases of insoluble and hydrophobic drugs, due to rapid disintegration and dissolution of these tablets.
• Stability for longer duration of time, since the drug remains in solid dosage form till it is consumed. So, it combines advantage of solid dosage form in terms of stability and liquid dosage form in terms of bioavailability.18

MATERIALS AND METHODS

Materials
Montelukast sodium was received as a gift sample from Hetero Drugs, Hyderabad, India. HPMC E5, E15, Maltodextrin was obtained from Lupin Research Park (Lupin Ltd). PEG 400, glycerin, aspartame, PVA was obtained from Research Lab Fine Chem Industries, Mumbai, India. Poonam A. Padamwar et al. / International Journal of Pharma Sciences and Research (IJPSR)

METHODS
Preparation of montelukast sodium oral thin films by Using 3² Full Factorial Designs

The fast dissolving oral film of the Montelukast sodium by using HPMC E15 and Maltodextrin is prepared by solvent casting method. In this first aqueous solution of the HPMC E15 and Maltodextrin is prepared by dissolving the HPMC E15 and Maltodextrin in distilled water. Montelukast sodium is added to the aqueous solution after that citric acid is added to the above solution followed by addition of the sweetener (Aspartame) and plasticizer.19 The solution was casted on the casting surface (mould, Petri dish) and dried at room temperature for 10 hours or dried into a Hot air oven for 6 hrs. Then film removed from the surface and cut into the desired size (2x2) of equivalent dose of Montelukast sodium. This preparation method was followed till completion of work.19

EVALUATION OF FAST DISSOLVING ORAL THIN FILM

Weight Variation

The weight variation test is determined by measuring the weight of the individual film of 2 cm x 2 cm area. For the measurement of the weight digital analytical balance was used. The weight of three films was measure and mean is taken.

Thickness

The thickness of strip was measured by digital vernier caliper at different locations. This is essential to ascertain uniformity in the thickness of the film as this is directly related to the accuracy of dose in the strip.

Folding endurance

Folding endurance is determined by repeated folding of the strip at the same place till the strip breaks. The number of times the film is folded without breaking is computed as the folding endurance value.

Tensile strength

Tensile strength of films was determined using an apparatus fabricated in laboratory. A small film strip (2 x 2 cm2) was cut and fixed to assembly. The weight required to break the film was noted and simultaneously film elongation was measured with the help of pointer mounted on the assembly. Measurements were done in triplicate for each batch. The mechanical properties tensile strength and % elongation were calculated for the fast dissolving film from the above measurements. Tensile strength is the ratio of maximum stress applied to a point at which the film specimen breaks and can be computed from the applied force at rupture to the cross sectional area of the fractured film as a mean of three measurements and described in the equation:
Tensile strength = Load at failure x 100 \ Strip Thickness X Strip Width

Percent elongation
When stress is applied, a strip sample stretches and this is referred to as strain. Strain is basically the deformation of strip divided by original dimension of the sample. Generally elongation of strip increases as the plasticizer content increases.

% Percent elongation = Increase in length of strip X 100 \ Initial length of strip

pH Value
The pH value can determine by dissolving one oral film in 10ml distilled water and measuring the pH of the obtained solution. It is necessary that film should have nearly uniform pH value.

Drug content
For determination of the drug content Montelukast sodium oral film equivalent to dose of 2.5 mg was dissolved in 50 ml of pH 6.8 buffer. The solution was sonicated for 10 minutes and then filtered through Whatman filter paper no. 41, to separate out the insoluble excipients. 1ml of filtrate was diluted to 100 ml with pH 6.8 buffer. The absorbance of resultant solution was measured using U. V. spectrophotometer at 285 nm and drug content was calculated.

Disintegration time
The disintegration for orally disintegrating tablets described in CDER guidance can be applied to oral film. Although, no official guidance is available for FDOF, this may be used as a qualitative guideline for quality control test or at development stage. But for the present work disintegration was measured by taking the 25 ml of distilled water in 50 ml beaker and individual film is dipped into that solution and disintegration time was recorded.

Surface texture
Surface texture was evaluated by visual appearance of oral film and categorized in smooth to rough surface indicates by mathematical + sign.

Moisture absorption
The film sample is weighed and placed on a pre-weighed stainless steel wire mesh. The wire mesh is then submerged in a Petridis containing 20 ml distilled water. Increase in weight of the film is determined at regular time intervals (10 min) until a constant weight is obtained the hydration ratio of the film is calculated and average moisture absorption is calculated and reported.

Hydration ratio = Wt-W0×100/W0
Where Wt = weight of film at time t and W0 = weight of film at zero time.

Moisture loss
The percent moisture loss was determined by placing prepared film in desiccators containing anhydrous calcium chloride. After three days, the film was taken and reweighed. Average percent moisture loss was calculated.

Content uniformity
The content uniformity test was used to ensure that every film contains the intended amount of drug content with little variation among films within a patch. Three pieces, each 6 cm2 (3 × 2 cm), were cut from the whole patch, and assayed for drug content. Same procedure was repeated for all the nine batches.

In Vitro Dissolution study
The in vitro release of drug from all formulations was determined using USP apparatus type II (Paddle method). The following conditions were followed to study the in-vitro dissolution study of Montelukast sodium Oral Film.
1. USP dissolution apparatus: Type II (Paddle method)
2. Volume of dissolution medium: 900 ml
3. Speed: 50 rpm
4. Temperature: 37±0.50 C
5. Dissolution medium: pH 6.8 buffer
6. Sampling interval: 1 min
7. Quantity of sample withdrawn: 5ml

Aliquots of dissolution medium of 5 ml were withdrawn at 1 min interval for 4 min. The volume withdrawn was replaced by fresh volume of dissolution medium. The filtered samples were analyzed spectrophotometrically at 285 nm and absorbance was noted. Cumulative percent drug release was calculated.
RESULTS

FT-IR Compatibility Study
Compatibility of drug and polymers was studied using Fourier Transform Infrared (FTIR) spectroscopy. FTIR Spectrum was recorded between 600-4000 cm\(^{-1}\) using Shimadzu 160a, Kyoto, Japan by KBrDisc method. The FTIR spectra of montelukast sodium and its physical mixtures are shown in figure 2. The FTIR spectrum of montelukast depicts a characteristic absorption band at 3437 cm\(^{-1}\) representing the presence of OH group. The CH\(_2\), C-N vibrations showed a characteristic absorption band in the region of 2926 cm\(^{-1}\) and 1265 cm\(^{-1}\). The spectrum of montelukast- polymer physical mixtures showed absorption bands at 3414 cm\(^{-1}\), 2926 cm\(^{-1}\) and 1266 cm\(^{-1}\) OH, CH\(_2\) and C-N. It indicates drug and drug containing physical mixture absorption bands were near that there was no chemical and physical change in the functional groups present in montelukast sodium.

![Figure 2: FT-IR spectra of a) Montelukast sodium, b) HPMC E 50 lv, c) HPMC e 15 lv, d) physical mixture of polymers and Montelukast sodium.](image)

Table 1. Evaluation of physico-mechanical parameters of fast dissolving film.

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Transparency</th>
<th>Weight variation (mg)</th>
<th>Thickness (mm)</th>
<th>Tensile strength (kg/Cm(^2))</th>
<th>Folding Endurance</th>
<th>Surface pH</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>Good</td>
<td>24.56±0.09</td>
<td>0.26±0.021</td>
<td>0.609±0.019</td>
<td>75±0.23</td>
<td>6.59±0.029</td>
</tr>
<tr>
<td>F2</td>
<td>Best</td>
<td>22.21±0.20</td>
<td>0.24±0.030</td>
<td>0.623±0.021</td>
<td>77±0.12</td>
<td>6.61±0.025</td>
</tr>
<tr>
<td>F3</td>
<td>Best</td>
<td>20.19±0.17</td>
<td>0.30±0.071</td>
<td>0.603±0.024</td>
<td>85±0.19</td>
<td>7.05±0.004</td>
</tr>
<tr>
<td>F4</td>
<td>Best</td>
<td>22.11±0.11</td>
<td>0.20±0.020</td>
<td>2.679±0.065</td>
<td>78±0.34</td>
<td>6.91±0.021</td>
</tr>
<tr>
<td>F5</td>
<td>Good</td>
<td>23.12±0.12</td>
<td>0.30±0.071</td>
<td>0.639±0.024</td>
<td>79±0.16</td>
<td>6.54±0.021</td>
</tr>
<tr>
<td>F6</td>
<td>Best</td>
<td>20.15±0.24</td>
<td>0.24±0.01</td>
<td>2.435±0.046</td>
<td>79±0.36</td>
<td>6.89±0.023</td>
</tr>
<tr>
<td>F7</td>
<td>Good</td>
<td>20.12±0.12</td>
<td>0.25±0.006</td>
<td>0.629±0.062</td>
<td>71±0.81</td>
<td>6.69±0.028</td>
</tr>
<tr>
<td>F8</td>
<td>Best</td>
<td>21.22±0.35</td>
<td>0.25±0.015</td>
<td>2.120±0.032</td>
<td>76±0.45</td>
<td>6.48±0.027</td>
</tr>
<tr>
<td>F9</td>
<td>Good</td>
<td>22.23±0.31</td>
<td>0.17±0.006</td>
<td>0.631±0.017</td>
<td>73±0.42</td>
<td>6.56±0.024</td>
</tr>
</tbody>
</table>

Table 2. Evaluation of physico-mechanical parameters of fast dissolving film.

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Surface texture</th>
<th>% Moisture absorption</th>
<th>% Moisture loss</th>
<th>% Drug content</th>
<th>In vitro disintegration time (s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>++ -</td>
<td>3.9±0.47</td>
<td>2.97±0.33</td>
<td>96.15±0.78</td>
<td>21.3±1.25</td>
</tr>
<tr>
<td>F2</td>
<td>++ -</td>
<td>2.4±0.54</td>
<td>3.32±0.09</td>
<td>90.34±0.12</td>
<td>16.3±1.17</td>
</tr>
<tr>
<td>F3</td>
<td>++ -</td>
<td>3.9±0.72</td>
<td>3.47±0.12</td>
<td>92.48±0.32</td>
<td>12.6±1.13</td>
</tr>
<tr>
<td>F4</td>
<td>+++</td>
<td>3.7±0.99</td>
<td>2.99±0.12</td>
<td>98.55±0.34</td>
<td>09.7±1.12</td>
</tr>
<tr>
<td>F5</td>
<td>+++</td>
<td>3.8±0.67</td>
<td>2.10±0.89</td>
<td>95.76±0.45</td>
<td>13.5±1.10</td>
</tr>
<tr>
<td>F6</td>
<td>++ -</td>
<td>4.5±0.54</td>
<td>3.93±0.14</td>
<td>97.41±0.54</td>
<td>12.5±1.14</td>
</tr>
<tr>
<td>F7</td>
<td>++ -</td>
<td>4.2±0.49</td>
<td>3.43±0.12</td>
<td>97.01±0.51</td>
<td>15.5±1.09</td>
</tr>
<tr>
<td>F8</td>
<td>+++</td>
<td>4.6±0.34</td>
<td>3.10±0.12</td>
<td>94.89±0.72</td>
<td>17.4±1.33</td>
</tr>
<tr>
<td>F9</td>
<td>++ -</td>
<td>4.7±0.77</td>
<td>3.45±0.13</td>
<td>96.90±0.70</td>
<td>14.7±1.02</td>
</tr>
</tbody>
</table>

(+) Indicates Smooth Surface, (-) Indicate Rough Surface
Table 3. Cumulative % Drug release of formulation F1 to F9.

<table>
<thead>
<tr>
<th>Time</th>
<th>F1</th>
<th>F2</th>
<th>F3</th>
<th>F4</th>
<th>F5</th>
<th>F6</th>
<th>F7</th>
<th>F8</th>
<th>F9</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 min</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>1 min</td>
<td>27%</td>
<td>28.5%</td>
<td>28.5%</td>
<td>34.5%</td>
<td>25.5%</td>
<td>27%</td>
<td>25%</td>
<td>26.85%</td>
<td>24.45%</td>
</tr>
<tr>
<td>2 min</td>
<td>49.5%</td>
<td>69%</td>
<td>73.5%</td>
<td>63%</td>
<td>57%</td>
<td>66%</td>
<td>60.5%</td>
<td>68.55%</td>
<td>64.5%</td>
</tr>
<tr>
<td>3 min</td>
<td>94.35%</td>
<td>96%</td>
<td>96.3%</td>
<td>99%</td>
<td>96.75%</td>
<td>97.35%</td>
<td>94.2%</td>
<td>97.95%</td>
<td>98.85%</td>
</tr>
</tbody>
</table>

Figure 3: invitrodissolution profile for oral thin films of Montelukast sodium.

The in-vitro drug release from film of all formulation was performed in triplicate using USP apparatus II (paddle method). Dissolution study was performed in pH 6.8 phosphate buffer. In case of F4 and F9 formulations about 99% and 98.85% of drug was released in 3 min. In case of F1, F7 formulation about 94.35% and 94.2% of drug released in 3 min. This drug release pattern indicates that the increased concentration of polymer decreases drug release and increased concentration of plasticizer increases drug release.

Accelerated stability study of optimized batch:
Stability of a drug has been defined as the ability of a particular formulation in a specific container, to remain within its physical, chemical, therapeutic and toxicological specifications. The purpose of stability study is to provide evidence on the quality of a drug substance or drug product which varies with time under the influence of a variety of environmental factors such as temperature, humidity and light. Recommended storage conditions, re-test periods and shelf lives are to be established. The International Conference of Harmonization (ICH) Guidelines titled, “stability testing of New Drug substance and products” (QIA) describes the stability test requirements for drug registration application in the European Union, Japan and the United States of America.

ICH specifies the length of study and storage conditions
- Long-term testing: - 250 C ± 20 C / 60 % RH ± 5% for 12 months.
- Accelerated testing: - 40 0 C ± 20 C / 75 % RH ± 5% for 6 months.

Accelerated Stability studies were carried out at 40 ± 20 C / 75 ± 5 % RH for the best formulations for 1 month.

Method: The best formulation was assessed their accelerated stability with respect to their appearance, in-vitro disintegration time, surface pH & drug release characteristics after storing them at 40 ± 20 C / 75 ± 5 % RH for 1 month.

Table 4. Results of Accelerated stability study.

<table>
<thead>
<tr>
<th>Batch</th>
<th>Appearance</th>
<th>Folding Endurance</th>
<th>Weight (Mg)</th>
<th>Disintegration Time (Sec)</th>
<th>Tensile Strength (kg/Cm²)</th>
<th>%Drug Content</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial</td>
<td>Transparent</td>
<td>78±0.34</td>
<td>31.38</td>
<td>09.7±1.12</td>
<td>2.679±0.065</td>
<td>98.55±0.34</td>
</tr>
<tr>
<td>After 1 Month</td>
<td>Transparent</td>
<td>80±0.26</td>
<td>29.23</td>
<td>11.2±1.08</td>
<td>2.158±0.043</td>
<td>97.22±0.12</td>
</tr>
</tbody>
</table>

Table 5. in vitro drug release profile of F4 batch after accelerated stability study.

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Initial</th>
<th>After 1 Month</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>0.5</td>
<td>34.5%</td>
<td>31.04%</td>
</tr>
<tr>
<td>1.5</td>
<td>63%</td>
<td>60.3%</td>
</tr>
<tr>
<td>2.5</td>
<td>99%</td>
<td>97%</td>
</tr>
</tbody>
</table>
CONCLUSION

In current research work, an effort has been made to prepare Fast dissolving Montelukast Sodium oral film by solvent casting method. The fast dissolving films of Montelukast Sodium were prepared by solvent casting technique using film forming polymers HPMC E15 and Maltodextrin. The prepared film disintegrates within twenty second which releases drug rapidly and gives antihypertensive action. As compared to that conventional dosage form, Fast dissolving Film has rapid onset of action. The optimized batch F4 was found to be stable for a period 1 months accelerated stability study at 40oc /75% RH.

REFERENCES